Micronization of cilostazol using supercritical antisolvent (SAS) process: Effect of process parameters

Powder Technology

Volumn 177, Issue 2, 2007, Pages 64-70

  Kim, Min Soo ^a   Lee, Sibeum ^a   Park, Jeong Sook ^a   Woo, Jong Soo ^b   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Cilostazol; Micronization; Poorly water soluble drug; Supercritical antisolvent

Indexed keywords

CONCENTRATION (PROCESS); DISSOLUTION; DRUG DOSAGE; PARTICLE SIZE; PRECIPITATION (CHEMICAL); PRESSURE VESSELS; SUPERCRITICAL FLUIDS; X RAY DIFFRACTION;

CILOSTAZOL; POORLY WATER SOLUBLE DRUG; SUPERCRITICAL ANTISOLVENT;

SOLVENTS;

CARBON DIOXIDE; CILOSTAZOL; GOLD; PALLADIUM; SOLVENT;

CONCENTRATION (PROCESS); DISSOLUTION; DRUG DOSAGE; PARTICLE SIZE; PRECIPITATION (CHEMICAL); PRESSURE VESSELS; SOLVENTS; SUPERCRITICAL FLUIDS; X RAY DIFFRACTION;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MORPHOLOGY; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; PRESSURE; PROCESS TECHNOLOGY; SCANNING ELECTRON MICROSCOPE; SUPERCRITICAL ANTISOLVENT PROCESS; TEMPERATURE; X RAY POWDER DIFFRACTION;

EID: 34547742600     PISSN: 00325910     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.powtec.2007.02.029     Document Type: Article

References (35)

1. Rogers T.L., Johnston K.P., and Williams III R.O. Drug Dev. Ind. Pharm. 27 (2001) 1003
2. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Eur. J. Pharm. Sci. 18 (2003) 113
3. Reverchon E. J. Supercrit. Fluids 15 (1999) 1
4. Pasquali I., Bettini R., and Giordano F. Eur. J. Pharm. Sci. 27 (2006) 299
5. Matson D.W., Fulton J.L., Petersen R.C., and Smith R.D. Ind. Eng. Chem. Res. 26 (1987) 2298
6. Turk M., Hils P., Helfgen B., Schaber K., Martin H.J., and Wahl M.A. J. Supercrit. Fluids 22 (2002) 75
7. Gosselin P.M., Thibert R., Preda M., and McMullen J.N. Int. J. Pharm. 252 (2003) 225
8. Yeo S.-D., Kim M.-S., and Lee J.-C. J. Supercrit. Fluids 25 (2003) 143
9. Won D.-H., Kim M.-S., Lee S., Park J.-S., and Hwang S.-J. Int. J. Pharm. 301 (2005) 199
10. Warwick B., Dehghani F., Foster N.R., Biffin J.R., and Regtop H.L. Ind. Eng. Chem. Res. 41 (2002) 1993
11. Chen K., Zhang X., Pan J., and Yin W. J. Cryst. Growth 274 (2005) 226
12. Yeo S.-D., and Kiran E. J. Supercrit. Fluids 34 (2005) 287
13. Jung J., and Perrut M. J. Supercrit. Fluids 20 (2001) 179
14. Hakuta Y., Hayashi H., and Arai K. Curr. Opin. Solid State Mater. Sci. 7 (2003) 341
15. Hayato U., Toshio T., Yukio K., and Hiroyoshi H. Biochem. Pharmacol. 33 (1984) 3339
16. Kimura Y., Tani T., Kanbe T., and Watanabe K. Arzneimittelforschung 35 (1985) 1144
17. Sorkin E.M., and Markham A. Drugs Aging 14 (1999) 63
18. G.W. Stowell, R.R. White, US Patent 6531603 (2003).
19. Jun S.W., Kim M.-S., Jo G.H., Lee S., Park J.-S., Woo J.S., and Hwang S.-J. J. Pharm. Pharmacol. 57 (2005) 1529
20. Lee S., Nam K., Kim M.-S., Jun S.W., Park J.-S., Woo J.S., and Hwang S.-J. Arch. Pharm. Res. 28 (2005) 866
21. Stowell G.W., Behme R.J., Denton S.M., Pfeiffer I., Sancilio F.D., Whittall L.B., and Whittle R.R. J. Pharm. Sci. 91 (2002) 2481
22. Wubbolts F.E., Bruinsma O.S.L., and van Rosmalen G.M. J. Cryst. Growth 198-199 (1999) 767
23. Thiering R., Dehghani F., and Foster N.R. J. Supercrit. Fluids 21 (2001) 159
24. Chang C.J., Day C.-Y., Ko C.-M., and Chiu K.-L. Fluid Phase Equilib. 131 (1997) 243
25. Bamberger A., Sieder G., and Maurer G. J. Supercrit. Fluids 17 (2000) 97
26. Shimizu T., Osumi T., Niimi K., and Nakagawa K. Arzneimittelforschung 35 (1985) 1117
27. Krober H., and Teipel U. J. Supercrit. Fluids 22 (2002) 229
28. Reverchon E., Della Porta G., De Rosa I., Subra P., and Letourneur D. J. Supercrit. Fluids 18 (2000) 239
29. Mukhopadhyay M. J. Supercrit. Fluids 25 (2003) 213
30. Reverchon E., De Marco I., and Della Porta G. Int. J. Pharm. 243 (2002) 83
31. Reverchon E., De Marco I., and Della Porta G. J. Supercrit. Fluids 23 (2002) 81
32. Suo Q.L., He W.Z., Huang Y.C., Li C.P., Hong H.L., Li Y.X., and Zhu M.D. Powder Technol. 154 (2005) 110
33. Bakhbakhi Y., Charpentier P.A., and Rohani S. Int. J. Pharm. 309 (2006) 71
34. ICH. Tripartite harmonized guideline Q3C, impurities: residual solvents. Fed. Regist. 68 (1997) 64352-64353
35. Cullity B.D. Elements of X-ray Diffraction. Second edition (1978), Addison-Wesley Publishing, Massachusetts 127